Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter  by Hohnloser, Stefan H. et al.
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eter Kowey, MD§
rankfurt and Hannover, Germany; Toronto, Canada; and Wynnewood, Pennsylvania
OBJECTIVES The goal of the present study was to assess the efficacy and safety of intravenous tedisamil, a
new antiarrhythmic compound, for conversion of recent-onset atrial fibrillation (AF) or atrial
flutter (AFL) to normal sinus rhythm (NSR).
BACKGROUND Tedisamil is a novel antiarrhythmic drug with predominantly class III activity. Its efficacy and
safety for conversion of recent onset AF or AFL to NSR is not known.
METHODS This was a multicenter, double-blind, randomized, placebo-controlled, sequential ascending
dose-group trial. A total of 201 patients with symptomatic AF or AFL of 3 to 48 h duration
were enrolled in a two-stage study. During stage 1, patients were randomized to receive
tedisamil at 0.4 mg/kg body weight or matching placebo; during stage 2, patients received
tedisamil at 0.6 mg/kg body weight or matching placebo. Treatments were given as single
intravenous infusions. The primary study end point consisted of the percentage of patients
converting to NSR for at least 60 s within 2.5 h.
RESULTS Of 175 patients representing the intention-to-treat sample, conversion to NSR was observed
in 41% (25/61) of the tedisamil 0.4 mg/kg group, 51% (27 of 53) of the tedisamil 0.6 mg/kg
group, and 7% (4/59) of the placebo group (p  0.001 for both tedisamil groups vs. placebo).
Average time to conversion was 35 min in patients receiving tedisamil. There were two
instances of self-terminating ventricular tachycardia: one episode of torsade de pointes and
one of monomorphic ventricular tachycardia, both in patients receiving 0.6 mg/kg tedisamil.
CONCLUSIONS Tedisamil at dosages of 0.4 and 0.6 mg/kg was superior to placebo in converting AF or AFL.
Tedisamil has a rapid onset of action leading to conversion within 30 to 40 min in the
majority of responders. (J Am Coll Cardiol 2004;44:99–104) © 2004 by the American
College of Cardiology Foundationa
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itrial fibrillation (AF) is the most common sustained
rrhythmia requiring hospitalization, and affects millions of
eople worldwide (1). The prevalence of AF increases with
ge and in the presence of structural heart disease (2). Atrial
brillation is associated with significant mortality and mor-
idity and impacts significantly on quality of life. Restora-
ion of normal sinus rhythm (NSR) in patients with these
rrhythmias may improve their hemodynamic condition,
elieve symptoms, and probably reduce embolic risk. Al-
hough this may be achieved using direct current cardiover-
ion, the technique has limitations such as the need for
eneral anesthesia and hospitalization. Accordingly, phar-
acologic conversion has been proposed as an alternative; a
ariety of antiarrhythmic drugs have been tested for this
urpose (3). However, many of these agents have important
ide effects such as the potential for proarrhythmia, impair-
ent of left ventricular function, or extracardiac unwanted
ffects. Consequently, there is a need to develop new
From the *J. W. Goethe University, Frankfurt, Germany; †St. Michel’s Hospital,
oronto, Canada; ‡Solvay Pharmaceuticals GmbH, Hannover, Germany; and §Lan-
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r. Straub and Mrs. Beckmann are employees of Solvay Pharmaceuticals.
Manuscript received December 1, 2003; revised manuscript received February 10,i004, accepted March 16, 2004.ntiarrhythmic drugs not only with good clinical efficacy but
lso with a favorable safety profile.
Tedisamil is a novel class III antiarrhythmic agent that
locks multiple potassium-channels and slows sinus rate. It
rolongs both atrial and ventricular action potential dura-
ion by blocking the transient outward Ito (4), the adenosine
riphosphate-dependent IK-ATP (5), and the delayed recti-
er potassium currents IKr, IKs, and IKur (6–8). Tedisamil
rolongs action potential duration more strongly in the atria
han the ventricles. The drug is not metabolized, is excreted
ia the kidney, and has a half-life of 8 to 13 h. Tedisamil
lso possesses significant antianginal and anti-ischemic
roperties (9). The present prospective, randomized, con-
rolled trial evaluated the efficacy and safety of tedisamil for
apid conversion of recent-onset AF or atrial flutter (AFL).
ETHODS
tudy population. The study protocol complied with all
ational and international ethical standards and was ap-
roved by the local institutional review board of all partic-
pating centers. Each patient gave written informed consent
efore enrollment. The study was conducted as a multi-
enter, double-blind, randomized, placebo-controlled, se-
uential ascending dose-group trial. Patients were entered
nto the trial from 34 centers applying the following
nclusion criteria: age 18 years; documented (60-s rhythm
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Tedisamil for Conversion of AF July 7, 2004:99–104trip), symptomatic AF or AFL of 3- to 48-h duration
either as a first or a recurrent episode); and a supine blood
ressure of 90 mm Hg systolic and 105 mm Hg
iastolic. The following exclusion criteria were applied:
ongestive heart failure New York Heart Association func-
ional class III/IV; acute coronary syndrome at the time of
andomization; acute myocardial infarction or percutaneous
oronary intervention within the previous 30 days; cardiac
urgery within the last 90 days; history of cerebrovascular
vents within the last six months; known Wolff-Parkinson-
hite syndrome; history of life-threatening ventricular
rrhythmias including torsade de pointes; previous electro-
ardiogram (ECG)-derived evidence of second or third
egree atrioventricular block; congenital long QT syn-
rome; QT interval470 ms before randomization; plasma
reatinine 1.8 mg/dl; serum potassium 4.0 mEq/l;
vidence of digitalis toxicity; concurrent therapy with anti-
rrhythmic drugs except beta-blockers, diltiazem, or digoxin
ot discontinued at least five half-lifes before randomiza-
ion; and treatment with amiodarone within the last three
onths.
tudy protocol. Eligible patients were stratified according
o the presence of AF or AFL and randomized to receive
ntravenous tedisamil or placebo. All patients were treated
n hospital under close surveillance. Specifically, continuous
CG monitoring via ECG telemetry and Holter monitor-
ng was performed starting 10 min before start of drug
nfusion until 24 h later. During stage 1, subjects were
andomized to receive a single infusion of tedisamil at a dose
f 0.4 mg/kg body weight or matching placebo (2:1 ratio);
uring stage 2, the dose of tedisamil was increased to 0.6
g/kg body weight (2:1 vs. placebo). Infusions were admin-
stered in 150 ml saline solution over a 30-min period with
alf of the dose given in the first 10 min and the remainder
ver the subsequent 20 min. A safety follow-up visit was
onducted 28 days after the end of the 24-h study period.
tatistical analysis. The primary objective of this study
as to demonstrate superiority of any dose of tedisamil over
lacebo in the termination of AF or AFL, as measured by
he percentage of patients converting to NSR for at least
0 s at any time within 2.5 h after the start of the treatment
nfusion. Secondary efficacy objectives included determina-
ion of the percentage of subjects who converted to NSR
ithin 2.5 h and remained in NSR until 24 h, and the time
o first conversion to normal NSR. Efficacy was evaluated
ccording to the intention-to-treat principle. For analysis,
lacebo patients enrolled in the two study stages were
Abbreviations and Acronyms
AF  atrial fibrillation
AFL  atrial flutter
ECG electrocardiogram/electrocardiographic
NSR  normal sinus rhythmombined. Differences in conversion rates were compared pmong treatment groups using the Pearson chi-square test.
istribution of times to conversion to NSR was described
y the Kaplan-Meier method and compared among treat-
ent groups using a Cox proportional hazards model with
actors for treatment group and center. The ECG changes
rom baseline were compared using two-sample t tests.
tatistical significance was assumed at a two-sided p value of
.05.
ESULTS
atient population. A total of 201 patients were random-
zed into the trial. Of these, 21 patients converted to NSR
efore they received treatment. Thus, the safety patient
ample consisted of 180 patients. In five patients, no
ontinuous ECG monitoring during drug infusion was
arried out (protocol violation), thus prohibiting acquisition
f efficacy data. Accordingly, efficacy results are based on
ata derived from 175 patients (Table 1).
rimary study end point. Two patients underwent direct
ardioversion within the first 2.5 h after start of drug
nfusion due to hemodynamic instability, which was not felt
o be a side effect of the medication according to the local
nvestigator. Of the remaining 173 patients without direct
urrent cardioversion, the percentage conversion to NSR for
t least 60 s within the first 2.5 h was 41% in the tedisamil
.4 mg/kg group (25 of 61 patients), 51% in the tedisamil
.6 mg/kg group (27 of 53 patients), and 7% (4 of 59
atients) in the placebo group (p 0.001 for both tedisamil
roups vs. placebo) (Fig. 1).
Analysis of efficacy according to the underlying arrhyth-
ia (i.e., AF vs. AFL) revealed the following results: of the
42 patients presenting with AF, 4 of 46 placebo patients
9%) converted to NSR. The respective numbers were 24 of
2 patients in the tedisamil 0.4 mg/kg group (46%) and 24
f 42 patients in the tedisamil 0.6 mg/kg group (57%) (p 
.001 for both tedisamil groups vs. placebo). Of the 33
atients presenting with AFL, the percentage conversion to
SR was 11% in the tedisamil 0.4 mg/kg group (1 of 9
atients), 27% in the tedisamil 0.6 mg/kg group (3 of 11
atients), and 0% in the 13 placebo patients (Fig. 1). The
ifference between the 0.6 mg/kg group and placebo
eached statistical significance (p  0.044).
Between 2.5 and 24 h after start of drug infusion, two
dditional patients on tedisamil 0.4 mg/kg, two on 0.6
g/kg, and nine patients on placebo converted to NSR.
econdary end points. Comparison of secondary efficacy
bjectives in patients with AF showed superiority of tedis-
mil 0.4 and 0.6 mg/kg over placebo for the percentage of
ubjects who converted to NSR within 2.5 h and remained
n NSR until 24 h, and the time to first conversion to NSR.
he respective numbers were 22 of 52 patients in the
edisamil 0.4 mg/kg group (42%) and 22 of 42 patients in
he tedisamil 0.6 mg/kg group (52%) (p  0.001 for both
edisamil groups vs. placebo). The percent of converted
atients versus time is displayed in Figure 2. The estimation
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July 7, 2004:99–104 Tedisamil for Conversion of AFf the hazard ratios to convert to NSR showed statistically
ignificant results in favor of both tedisamil groups (hazard
atios: 2.46 [95% confidence intervals: 1.26 to 4.79] and
.32 [1.70 to 6.48], respectively; p  0.01 for both groups
s. placebo). The mean (SD) time to NSR conversion was
5  27 min and 34  21 min for tedisamil 0.4 mg/kg and
.6 mg/kg, respectively.
afety. Two patients randomized to placebo died during
he study period. One patient died before the start of the
nfusion from recurrent pulmonary embolism caused by
Table 1. Patient Characteristics at Baseline
Gender
Male
Female
Age (yrs) 6
Concomitant therapy*
Beta-blocking agents
Digitalis glycosides
Agents acting on the renin-angiotensin system
Diuretics
Calcium channel blockers
Heart rhythm
Atrial fibrillation
Atrial flutter
CHF NYHA functional class
I
II
Duration (h) of current arrhythmia episode
Mean (SD) 21
Median
Min-max
*Concomitant medication was defined as medication taken
including medications started before randomization and med
CHF  congestive heart failure; NYHA  New York H
igure 1. Cumulative incidence of drug-associated conversion to normal s
ith atrial fibrillation (Afib) or atrial flutter (Aflu) and in the entire patient poostoperative immobility. The other patient died from
ancreatic carcinoma leading to respiratory failure 18 days
fter start of infusion. The incidence of patients with at least
ne treatment-emergent adverse event was dose-dependent
nd occurred in 38 patients (58%) in the tedisamil 0.4
g/kg group, in 42 patients (78%) in the tedisamil 0.6
g/kg group, and in 35 patients (57%) in the placebo group
safety sample). Only the difference between the tedisamil
.6 mg/kg group and the placebo group was statistically
ignificant (p  0.02). Most frequently reported tedisamil
Treatment Group, n (%)
amil
g/kg
Tedisamil
0.6 mg/kg Placebo Total
68%) 31 (58%) 34 (58%) 108 (62%)
32%) 22 (42%) 25 (42%) 67 (38%)
13.0 63.7  14.7 65.0  13.6 63.6  13.7
78%) 33 (61%) 39 (64%) 123 (68%)
15%) 16 (30%) 18 (30%) 44 (24%)
40%) 31 (57%) 28 (46%) 85 (47%)
34%) 14 (26%) 18 (30%) 54 (30%)
25%) 15 (28%) 21 (34%) 52 (29%)
86%) 42 (79%) 46 (78%) 142 (81%)
14%) 11 (21%) 13 (22%) 33 (19%)
73%) 30 (57%) 35 (59%) 111 (63%)
22%) 21 (40%) 24 (41%) 59 (34%)
13.12) 25.02 (12.01) 25.65 (12.83) 24.11 (12.73)
.8 24.7 24.7 23.5
8.3 4.9–47.8 4.8–53.0 1.7–53.0
g the double-blind period or the 28-day follow-up period
ns started during the study.
ssociation; SD  standard deviation.
hythm (NSR) within the first 2.5 h after drug administration in patientsTedis
0.4 m
43 (
20 (
2.1 
51 (
10 (
26 (
22 (
16 (
54 (
9 (
46 (
14 (
.98 (
18
1.7–4
durin
icatio
eart Ainus r
pulation. Numbers in parentheses indicate patients treated.
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Tedisamil for Conversion of AF July 7, 2004:99–104dverse events were (recurrent) AF (8% in the 0.4 mg
edisamil group, 9% in the 0.6 mg tedisamil group, and 2%
n the placebo group), bradycardia (2% in the 0.4 mg
edisamil group, 15% in the 0.6 mg tedisamil group, and 9%
n the placebo group), injection site burning/pain (9% in the
.4 mg tedisamil group, 8% in the 0.6 mg tedisamil group,
nd 0% in the placebo group), first degree atrioventricular
lock (0% in the 0.4 mg tedisamil group, 9% in the 0.6 mg
edisamil group, and 5% in the placebo group), and ventric-
lar tachycardia (3% in the 0.4 mg tedisamil group, 7% in
he 0.6 mg tedisamil group, and 2% in the placebo group).
wo of these ventricular tachycardias were considered to
igure 2. Kaplan-Meier estimates for time to first conversion to normal
inus rhythm (NSR) in patients presenting with atrial fibrillation.
Table 2. Electrocardiographic Data
Tedisami
0.4 mg/kg
n Mean
Heart rate (beats/min)
Baseline 61 103 (2
Change from baseline 60 17 (2
p value (compared to placebo) 0.0
RR (ms)
Baseline 61 622.9 (1
Change from baseline 60 165.1 (2
p value (compared to placebo) 0.0
QRS (ms)
Baseline 63 88.9 (2
Change from baseline 61 1.4 (8
p value (compared to placebo) 0.3
QT (ms)
Baseline 63 337.9 (3
Change from baseline 61 48.2 (5
p value (compared to placebo) 0.0
QTc (Bazett) (ms)
Baseline 61 435.7 (3
Change from baseline 60 10.8 (4
p value (compared to placebo) 0.1SD  standard deviation.epresent relevant proarrhythmic events by an independent
afety and monitoring committee. Both occurred in the
edisamil 0.6 mg/kg group in AF patients and consisted of
ne episode of a nonsustained polymorphic ventricular
achycardia of the torsade de pointes type and of one
pisode of sustained monomorphic ventricular tachycardia.
he torsade de pointes occurred 44 min after start of drug
nfusion in an 87-year-old female with a baseline QTc of
47 ms and a serum K concentration of 4.4 mEq/l. The
pisode of nonsustained monomorphic ventricular tachycar-
ia occurred in a 55-year-old female with a baseline QTc of
00 ms and a serum K concentration of 4.3 mEq/l.
either of the two events required cardioversion.
CG data. Mean RR and QT intervals increased in a
ose-dependent manner (Tables 2 and 3) and returned to
aseline within approximately 4 h. Twenty-eight percent of
lacebo patients, 25% of those receiving 0.4 mg/kg, and
6% of those receiving 0.6 mg/kg tedisamil showed at least
nce during the 24-h observation period a QTc value of
500 ms. An increase from baseline of60 ms in QTc was
bserved in 22%, 27%, and 41% of patients, respectively.
ight patients showed QT interval prolongation of 550
s: two (3%) from the tedisamil 0.4 mg/kg group and six
11%) from the tedisamil 0.6 mg/kg group.
ISCUSSION
he results of this randomized placebo-controlled study
emonstrate that intravenously administered tedisamil is
ffective in the acute conversion of patients with AF or AFL
f up to 48 h duration. There was a conversion rate of 46%
Treatment
Tedisamil
0.6 mg/kg Placebo
n Mean (SD) n Mean (SD)
51 103 (26) 57 102 (26)
51 25 (28) 56 0 (13)
0.001
51 628.5 (185.0) 57 624.5 (157.1)
51 230.1 (269.9) 56 0.8 (78.8)
0.001
52 94.5 (17.9) 58 88.7 (19.0)
51 2.5 (11.8) 57 0.1 (7.0)
0.161
52 347.8 (52.4) 58 347.3 (47.1)
51 74.7 (70.6) 57 1.6 (23.7)
0.001
51 443.1 (40.5) 57 443.4 (39.8)
50 16.9 (45.2) 56 1.5 (28.8)
0.037l
(SD)
5)
3)
01
75.0)
15.8)
01
1.3)
.8)
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July 7, 2004:99–104 Tedisamil for Conversion of AFbserved with 0.4 mg/kg tedisamil and of 57% at a dose of
.6 mg/kg. There was a rapid onset of action with an
verage time to cardioversion of 35 min after start of
edisamil administration.
revious studies. Most antiarrhythmic drugs have only
imited efficacy for rapid pharmacologic conversion of AF or
FL, particularly when given orally. An exception to this
ule are class IC drugs such as flecainide or propafenone
10–13). Cumulative conversion rates of up to approxi-
ately 75% within 8 to 12 h after oral drug administration
ave been reported. After intravenous administration, con-
ersion rates within the first 2 h ranged between 39% and
0% (10–13). However, there are some important limita-
ions to these agents. The intravenous formulations of these
rugs are not available in many countries (such as the U.S.).
oreover, class IC drugs have negative inotropic and
ignificant proarrhythmic side effects that limit their use in
atients with structural heart disease (14).
A number of class III antiarrhythmic agents have also
een tested for acute termination of AF or AFL. For
nstance, amiodarone has been the subject of several smaller
tudies (13). However, due to its complex pharmacody-
amic and pharmacokinetic properties, no single dosing
ecommendation has gained widespread acceptance. Even
hen given in relatively large doses intravenously, the onset
f action of amiodarone in converting AF is often delayed,
nd it usually takes24 h to achieve a significant effect (13).
onversion rates ranged between 6% and 20% for the first
h of drug administration (13). Amiodarone is not ap-
roved for conversion of AF in the U.S.
Ibutilide is another class III antiarrhythmic drug that
elays repolarization predominantly by activating a slow
nward sodium current (15). After having been tested in
everal controlled randomized studies (16–19), intravenous
butilide has recently been approved for the acute conversion
f AF and AFL. In an initial dose-ranging study, ibutilide
howed a conversion efficacy between 12% and 46% (16). In
comparative study, ibutilide converted 58% of patients
ith AF compared with 18% when intravenous procain-
mide was given (18). The drug carries a definite proar-
Table 3. Heart Rate Changes During Tedisam
n
Baseline 6
All patients (data obtained at 30 min)
Change from baseline 6
All patients (data obtained before conversion for
converters to NSR within 30 min)
Change from baseline 6
Nonconverters (data obtained at 30 min)
Change from baseline 4
NSR  normal sinus rhythm; SD  standard deviation.hythmic risk of torsade de pointes that ranges between 2% and 5% and has led to important restriction regarding its use
15).
The efficacy rates observed for tedisamil in the present
tudy compare favorably to these agents, particularly in
atients presenting with AF. Importantly, the spontaneous
onversion rate in patients randomized to placebo was only
% in the first 2.5 h after start of the infusion. In patients
ith AFL, only the higher tedisamil dose achieved a
tatistically significant conversion effect. This is in contrast
ith other class III agents such as ibutilide, which seems to
ave better efficacy rates in AFL. However, the present
tudy included only a relatively small number of patients
ith AFL. Therefore, more data are needed to clarify
edisamil’s efficacy in converting this arrhythmia.
afety aspects. Tedisamil was well-tolerated in the major-
ty of patients. The most frequently encountered side effect
as pain or burning sensations at the site of drug infusion.
here were two instances of serious ventricular tachy-
rrhythmic events: one episode of monomorphic spontane-
usly terminating ventricular tachycardia and one episode of
onsustained torsade de pointes. Particularly, the latter may
epresent a drug-associated proarrhythmic effect, which
mphasizes the need for close surveillance of patients when
ttempting acute pharmacologic cardioversion by means of
dministration of class III antiarrhythmic compounds. The
verall incidence of potential proarrhythmic reactions was
hus 1.8% (2 of 114 patients), a number that compares
avorably with the incidence of proarrhythmia associated
ith the use of ibutilide (15–19). It is important to note in
his regard that tedisamil caused a significant increase in the
R interval (Table 2). As a consequence from the observa-
ions of this study it is recommended that close surveillance
ncluding ECG monitoring for approximately 8 h after drug
dministration be performed.
linical summary. This is the first clinical evaluation of
he cardioversion efficacy and safety of intravenously admin-
stered tedisamil, a new class III antiarrhythmic agent. The
esults of this prospective dose-finding study demonstrate
hat this compound may represent a valuable addition to the
rmamentarium of antiarrhythmic drugs used to treat this
ministration
Treatment
disamil
mg/kg
Tedisamil
0.6 mg/kg Placebo
ean (SD) n Mean (SD) n Mean (SD)
103 (25) 51 103 (26) 57 102 (26)
17 (23) 51 25 (28) 56 0 (13)
10 (20) 51 16 (26) 56 0 (13)
12 (21) 38 20 (28) 56 0 (13)il Ad
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7rrhythmia. Further data are warranted, including on lower
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Tedisamil for Conversion of AF July 7, 2004:99–104edisamil dosages (potentially resulting in enhanced safety)
nd higher dosages (potentially enhanced efficacy).
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PPENDIX
or a list of the participating study centers, please see the July
, 2004, issue of JACC at http://www.cardiosource.com/
acc.html.
